Premium
SENP1 participates in Irinotecan resistance in human colon cancer cells
Author(s) -
Chen MingCheng,
Nhan Do Chi,
Hsu ChiungHung,
Wang TsoFu,
Li ChiCheng,
Ho TsungJung,
Mahalakshmi B.,
Chen MeiChih,
Yang LiangYo,
Huang ChihYang
Publication year - 2021
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29946
Subject(s) - colorectal cancer , sumo protein , irinotecan , cancer research , gene knockdown , angiogenesis , biology , mouse model of colorectal and intestinal cancer , downregulation and upregulation , cancer , gene , biochemistry , genetics , ubiquitin
Colorectal cancer is one of the most prevalent cancers in the world. Chemoresistance has always been a problem encountered in its treatment. It is known that SUMOylation may regulate protein stability and decomposition, and even affect the protein translocation and posttranslational modification in cells. Sentrin‐specific protease 1 (SENP1) is involved in the maturation of SUMO protein, and on the other hand, plays a role in deSUMOylation, which dissociates the target protein from SUMO and prevents further degradation of the target protein. In this study, we established an Irinotecan (CPT‐11) resistant human colon cancer LoVo strain (LoVo R‐CPT‐11 ) to investigate the role of SENP1 in the development of drug resistance in colorectal cancer. The abundant accumulation of SENP1 and HIF‐1α proteins and the increase of SUMO pathway enzymes were observed in LoVo R‐CPT‐11 cells while the protein markers of proliferation, angiogenesis, and glycolysis were upregulated. Knockdown of SENP1 reduced the migration ability and trigged re‐sensitivity of LoVo R‐CPT‐11 cells to CPT‐11 treatment. The analysis of SENP1 and HIF‐1α gene expressions from TCGA/GTEx datasets using the GEPIA web server showed a positive correlation between SENP1 and HIF‐1α in colorectal cancer patients and the high expression of these two genes might predict a poor outcome clinically. In conclusion, SENP1 might play an important role in CPT‐11 resistance in colorectal cancer. Targeting SENP1 to reduce the resistant property could be considered in prospective clinical studies.